Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study-Should we extend the boundaries?

Affiliations

¹ Department of Internal MedicinePostgraduate Institute of Medical Education and ResearchChandigarhIndia.
² Department of HepatologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia.

Comment

Parakh Gulati et al. Hepatology. 2022 Oct.

. 2022 Oct;76(4):E80-E81.

doi: 10.1002/hep.32554. Epub 2022 Jun 30.

¹ Department of Internal MedicinePostgraduate Institute of Medical Education and ResearchChandigarhIndia.
² Department of HepatologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia.

No abstract available

Comment on

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Gaillard VE, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ. D'Alessio A, et al. Hepatology. 2022 Oct;76(4):1000-1012. doi: 10.1002/hep.32468. Epub 2022 Apr 8. Hepatology. 2022. PMID: 35313048 Free PMC article.

1. D’Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study. Hepatology. 2022;76:1000–12.
1. Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, et al. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol. 2014;20(3):786–94.
1. Choo SP, Nahon P. Atezolizumab and bevacizumab for HCC in the real world. Liver Int. 2022;42(4):727–8.
1. Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–73.